Tropical endomyocardial fibrosis (EMF) remains a mysterious and challenging cardiovascular disease. The condition is characterized by the deposition of fibrous tissue in the endomyocardium, leading to restrictive physiology. EMF affects mainly the poorest populations and is likely to be the leading cause of restrictive cardiomyopathy in the developing world.1–3

The phenotypic expression is variable, according to the stage at which it is diagnosed, usually leading to heart failure and premature death in children and adolescents.2 EMF has remained poorly understood since its first description in 1948.4–6 Investment in research has been extremely limited, with EMF appearing neither on the public health agenda of developed countries nor among the scientists from developing countries.1 The mechanisms of EMF thus remain poorly understood since its first description in 1948.4–8 Investment in research has been extremely limited, thereby precluding the development of effective prevention and therapeutic strategies. The pathogenesis might combine genetic and environmental factors, which could explain the distribution of the disease in specific geographic hot spots worldwide.3

Untreated EMF carries a very poor prognosis, and there is no specific management so far. Early surgery appears to improve outcomes to some extent;9,10 however, surgery is technically challenging and not available in most endemic areas. Increased awareness among health workers and policy makers is the need of the hour for the unhindered development of efficient preventive and therapeutic strategies. (Circulation. 2016;133:2503-2515. DOI: 10.1161/CIRCULATIONAHA.115.021178.)

Key Words: endomyocardial fibrosis ■ epidemiology ■ health services accessibility ■ heart failure ■ mortality

© 2016 American Heart Association, Inc.

Circulation is available at http://circ.ahajournals.org

DOI: 10.1161/CIRCULATIONAHA.115.021178

Tropical Endomyocardial Fibrosis
Natural History, Challenges, and Perspectives

Antonio Grimaldi, MD; Ana Olga Mocumbi, MD, PhD; Juergen Freers, MD; Matthias Lachaud, MD; Mariana Mirabel, MD, PhD; Beatriz Ferreira, MD, PhD; Kumar Narayanan, MD; David S. Celermajer, PhD, FRACP; Daniel Sidi, MD, PhD; Xavier Jouven, MD, PhD; Eloi Marijon, MD, PhD

Abstract—Tropical endomyocardial fibrosis (EMF) is a neglected disease of poverty that afflicts rural populations in tropical low-income countries, with some certain high-prevalence areas. Tropical EMF is characterized by the deposition of fibrous tissue in the endomyocardium, leading to restrictive physiology. Since the first descriptions in Uganda in 1948, high-frequency areas for EMF have included Africa, Asia, and South America. Although there is no clear consensus on a unified hypothesis, it seems likely that dietary, environmental, and infectious factors may combine in a susceptible individual to give rise to an inflammatory process leading to endomyocardial damage and scar formation. The natural history of EMF includes an active phase with recurrent flare-ups of inflammation evolving to a chronic phase leading to restrictive heart failure. In the chronic phase, biventricular involvement is the most common presentation, followed by isolated right-sided heart disease. Marked ascites out of proportion to peripheral edema usually develops as a typical feature of EMF. EMF carries a very poor prognosis. In addition to medical management of heart failure, early open heart surgery (endocardectomy and valve repair/replacement) appears to improve outcomes to some extent; however, surgery is technically challenging and not available in most endemic areas. Increased awareness among health workers and policy makers is the need of the hour for the unhindered development of efficient preventive and therapeutic strategies. (Circulation. 2016;133:2503-2515. DOI: 10.1161/CIRCULATIONAHA.115.021178.)

Key Words: endomyocardial fibrosis ■ epidemiology ■ health services accessibility ■ heart failure ■ mortality

From Cardiovascular and Thoracic Department, San Raffaele Hospital, Milan, Italy (A.G.); St. Raphael of St. Francis Nsamba Hospital, Kampala, Uganda (A.G.); Paris Cardiovascular Research Center (INSERM U970), Cardiology & Development, Paris, France (M.M., K.N., X.J., E.M.); Instituto Nacional de Saude, Maputo, Mozambique (A.O.M.); Division of Cardiology, Department of Medicine, Makerere University, Kampala, Uganda (J.F.); Institut du Thorax, Nantes, France (M.L.); Maputo Heart Institute, Maputo, Mozambique (M.L., B.F., D.S., X.J., E.M.); European Georges Pompidou Hospital, Cardiology Department, Paris, France (M.M., X.J., E.M.); Necker Enfants Malades Hospital, Pediatric Cardiology, Paris, France (D.S.); Maxcure Hospitals, Hyderabad, India (K.N.); Sydney Medical School, Sydney, Australia (D.S.C.); and Paris Descartes University, Paris, France (D.S., X.J., E.M.).

Correspondence to Eloi Marijon, MD, PhD, Paris Descartes University, European Georges Pompidou Hospital, Cardiology Department, 20-40 Rue Leblanc, 75908 Paris Cedex 15, France. E-mail eloimarijon@yahoo.fr

(Circulation. 2016;133:2503-2515. DOI: 10.1161/CIRCULATIONAHA.115.021178.)

© 2016 American Heart Association, Inc.

Circulation is available at http://circ.ahajournals.org

DOI: 10.1161/CIRCULATIONAHA.115.021178

2503
sporadic cases have also been reported in Congo and Malawi, among others.14–24 India has witnessed a striking burden of EMF along the coastal area and rain forest of Kerala State,25–27 and in China, a high prevalence has been found in the province of Guangxi.28 In South America, EMF has been reported mainly in Brazil and Colombia.29,30 A community-based study carried out with systematic echocardiography to capture also subclinical disease, documented a striking burden of EMF, with an estimated prevalence rate up to almost 20%.31,32,33 of the general population in a rural community in Mozambique (100 km north of Maputo). A recent decline observed in India and some regions of Nigeria contrasts with the persistent high trends in other areas, underlining the potential influence of socioeconomic and environmental factors on the disease.32–38

EMF affects predominantly impoverished young adults of lower socioeconomic status, with a bimodal distribution peaking at 10 and 30 years of age.3,14,20 Data on sex distribution are mixed. In women, ages of childbearing age present a 2-fold higher prevalence compared with men.34 By contrast, other studies have not observed a specific sex difference in adults,33,14,20 and a male preponderance has been reported in Mozambique31 and Nigeria.32,42

The long-term outcome from medical treatment in advanced stages is very poor, with 75% mortality at 2 years.43 Overall, EMF accounts for ~20% of hospitalizations for heart failure in India, Equatorial Guinea, and Uganda,6,44,45 where the disease represents the second leading cause of pediatric admission for acquired heart disease, after rheumatic heart disease.46

Origin and Pathogenesis

The pathogenesis of EMF remains unclear, and there is a need for more systematic research and the use of contemporary technologies to test older, classic hypotheses, which have varied across studies. Poverty, malnutrition, parasitic infestations, genetics, and cluster ethnicity have all been proposed as causes/cofactors. The various theories advanced for the etiopathogenesis of EMF are revisited below.

Eosinophilia, Infectious Disease, and Autoimmunity

Similarities with the Loffler syndrome57,48 and the prevalence of parasites in the endemic countries26,27 led to consider eosinophilia and infections as potential primary triggers.49–53 An excessive immune response to the trigger (Figure 1) has been suggested to be the link between certain parasitic infections and EMF.54–59 This has been demonstrated, for example, by increased circulating levels of IgG53,60,61 and the occurrence of hyperimmune malaria-related splenomegaly among Rwandan immigrants affected by EMF.62 Immunological investigations have revealed the presence of autoantibodies (IgG and IgM) directed against myocardial proteins.58,63 However, the peculiar fact that eosinophils are limited only to the early stages of EMF,53 the inconsistent geographical matching with important parasitic infections (eg, schistosomiasis and filariasis in Southeast Asia),64–66 and the lack of difference in parasitic loads between EMF patients compared with control subjects all argue against a straightforward parasitic-related immunological mechanism.57,66 The disease afflicts individuals in rural settings, which are also endemic for malaria, but again, geographic distributions of EMF and malaria have not matched in a coherent fashion to allow causal links to be drawn.50,69–79 Furthermore, malaria has never been described as being associated with myocardial or endocardial damage.80

The concept of molecular mimicry, similar to rheumatic heart disease,72,73 has also been proposed as a mechanism but without compelling evidence.74

Environmental Factors, Dietary Factors, and Toxins

Although several environmental/toxic factors such as magnesium deficiency, cerium toxicity, the cyanogenic glycosides, high vitamin D, serotonin toxicity,55,59,62,81–86 and, more recently, the potential effect of certain herbal preparations,97 have been advocated in the pathogenesis, no confirmatory evidence firmly establishes these hypotheses. It has been speculated that, in genetically predisposed people, poor diet per se may lead to a dysfunction in the regulatory and functional mechanisms of eosinophils, which, as in eosinophilic leukemia, may cause necrosis, thrombosis, and finally fibrosis.67 This is supported by the fact that long-standing dietary imbalance with low-protein intake is generally seen along with EMF.12

One of the more popular diet-related hypotheses has proposed an important role for cassava, which is almost universally consumed in certain areas of Africa and other developing areas. Cassava (Manihot esculenta Crantz), a tuber, is an important dietary staple for >500 million people in developing countries because it is cheaper than other carbohydrate sources, especially rice and maize. Cassava contains a toxic cyanogenic glycoside called linamarin that can liberate hydrogen cyanide in the gut during digestion. In the absence of proper processing/cooking methods, toxic levels of the glycoside may persist in the tuber during consumption. Normally, cyanide is detoxified in the body by conversion to thiocyante via the sulfur-containing enzyme rhodanase. A low-protein diet, especially if deficient in sulfur-containing amino acids, may decrease the detoxification capacity and thus increase vulnerability to the toxic effects of cyanide.99 This can be compounded by excessive consumption of cassava as the sole source of dietary energy and protein. Tissue hypoxia and lipid peroxidation occurring from sublethal doses of cyanide might alter myocardial cell biology, as can be seen with neuronal toxicity.100 In animal models, the development of intracellular vacuoles, endocardial thickening, and interstitial fibrosis has been demonstrated with cassava intake, and this process was seen to be independent of eosinophilia or parasitic infestation. Furthermore, the fact that improved socioeconomic status and a significant drop in cassava intake paralleled a decline in EMF rates in Kerala, India, adds some credence to a role for cassava. However, certain inconsistencies remain such as the mismatch between the distribution of EMF and malnutrition in Africa and the occurrence of the disease among subjects from nontropical areas who have spent only a short time in endemic areas.57,76,93,94

It bears mention that malnutrition may also contribute to the pathogenesis of EMF by increasing susceptibility to parasitic infections.34 Finally, the higher prevalence of right-sided
heart disease suggests a role for potentially toxic factors removed by the lung.15

Genetic Susceptibility
Genetic susceptibility has also been proposed as a potential explanation for the high prevalence of EMF in specific areas.3,13,27,101 Instances of familial occurrence3,62,95 and rare cases among very young children102–105 suggest the existence of a genetic predisposition, although exposure to environmental factors during the antenatal period may explain some early-life cases.105

Ethnic clustering of cases3,62,95,96 has also suggested the role of genetics; however, this has been recently challenged by other data. For instance, in Uganda, EMF is more common among immigrants from neighboring Rwanda and Burundi,13 but it also occurs in whites who have lived in endemic regions57,76,93,94 or in immigrants coming from areas where the disease is anecdotal. Thus, the role of genetic predisposition in EMF is unclear at present and needs further study.

Summary of Etiopathogenesis
Although there is no clear consensus on a unified hypothesis, it seems likely that dietary, environmental, and infectious factors may combine in a susceptible individual to give rise to an inflammatory process leading to endomyocardial damage and scar formation (Table 1). There is an urgent need to better understand the underpinnings of this disease to develop effective interventions.

Natural History and Presentation
Contrasting with the still obscure pathogenesis, the natural history of EMF has been well documented (Figure 1) and includes an active phase with recurrent flare-ups of inflammation evolving to a chronic phase leading to restrictive heart failure.
Active Form: Inflammation
EMF usually starts with a febrile illness associated with pancarditis and eosinophilia, dyspnea, itching, and periorbital swelling.\(^49, 53, 106, 107\) There is no specific biological marker for EMF, with eosinophilia at diagnosis varying widely between absent and 70%.\(^34, 68\) Higher rates are reported in the early stages, and peculiarly, the circulating eosinophils are often morphologically abnormal.\(^68\) Acute inflammation of the heart\(^107, 108\) results in myocardial edema, eosinophilic infiltration, subendocardial myofiber necrosis, and vasculitis. The ECG is nonspecific and may show low-voltage QRS, ST–T–wave changes, conduction disturbances, and atrial or ventricular arrhythmias.\(^24\) On echocardiography, homogeneous infiltrates fill in layers of the cardiac walls (Figure 2A), and pericardial effusion is common. Mural thrombi may also occur along the endocardial surfaces of the apical and valvular pockets; at this stage, thromboembolic events are frequent. Subsequently, as the inflammatory process declines and eosinophils become undetectable,\(^69, 109, 110\) both interstitial fibrosis and myocyte hypertrophy develop and may lead to myocardial ischemia\(^111\) and cicatricial fibrosis (chronic phase; Figure 2B). The clinical distinction of the active phase of EMF from acute rheumatic fever in these endemic areas can be challenging.\(^22, 49\) An unknown number of cases evolve rapidly to heart failure and death, whereas other individuals pass through a subacute “burnout” phase without sequelae.\(^39\)

Transient Progressive Form: Toward the Chronic Phase
Similar to rheumatic heart disease, the recurrence of active episodes may facilitate the evolution to the chronic phase of EMF.\(^108\) With such an evolution, systemic inflammation becomes rare,\(^13, 107, 108\) and markers of inflammatory activity such as hypoalbuminemia and liver or kidney dysfunction are rarely observed. As chronic heart failure develops, edema and ascites become manifest. One distinguishing feature is that the ascitic fluid in patients with EMF is mostly exudative with a pleocytosis of white blood cells, mostly lymphocytes. Radiological signs are usually nonspecific, show varying degrees of cardiomegaly, and only exceptionally reveal the typical linear endocardial calcifications.\(^11\) On echocardiography, as the myocardium returns to normal thickness, the affected areas unevenly evolve into endocardial scars (Figure 2B and 2C), and a restrictive syndrome occurs with chamber distortion and dilated atria (Figure 2D). Typically, the fibrotic process stops abruptly just before the ventricular outflow tract. The occurrence of endomyocardial calcification spots is usually a marker of burnt-out disease\(^33\) resulting from intermittent flare-ups of inflammation alternating with quiescent phases.

To date, the factors responsible for the evolution of the disease and the basis for fast-progression versus slow-progression phenotype (that remain asymptomatic for a long period of time) remain poorly understood.

Chronic Form
In the chronic phase, biventricular involvement is the most common presentation (up to 55%),\(^1\) followed by isolated right-sided heart involvement and, in rare cases, isolated left-sided heart disease. When right ventricular restriction predominates, the long-standing systemic venous hypertension

<table>
<thead>
<tr>
<th>Table 1. Proposed Causes of EMF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Eosinophilia and parasitic disease</strong></td>
</tr>
<tr>
<td>Eosinophilia</td>
</tr>
<tr>
<td>Immuno-allergy inducers</td>
</tr>
<tr>
<td>Schistosomiasis</td>
</tr>
<tr>
<td>Filarisias</td>
</tr>
<tr>
<td>Virus, mycoplasma pneumonia, Toxoplasma gondii</td>
</tr>
<tr>
<td>Malaria</td>
</tr>
<tr>
<td>Autoimmunity</td>
</tr>
<tr>
<td>Streptococcal infection and rheumatic heart disease</td>
</tr>
<tr>
<td><strong>Alimentation and toxicity</strong></td>
</tr>
<tr>
<td>Magnesium deficiency</td>
</tr>
<tr>
<td>Cassava toxicity</td>
</tr>
<tr>
<td>High vitamin D</td>
</tr>
<tr>
<td>Serotonin</td>
</tr>
<tr>
<td>Cerium and thorium</td>
</tr>
<tr>
<td>Traditional medicinal plants</td>
</tr>
<tr>
<td><strong>Genetic susceptibility</strong></td>
</tr>
</tbody>
</table>

EMF indicates endomyocardial fibrosis.
results in facial edema and exophthalmos, jugular venous distension, gross hepatomegaly, congestive splenomegaly, and abdominal swelling.\textsuperscript{1,112} Marked ascites\textsuperscript{113} out of proportion to peripheral edema (Figure 3) usually develops as a typical feature of both right- and left-sided heart EMF. Abundant ascites with lymphocytic exudates and peritoneal fibrosis but without pedal edema had led researchers to propose an EMF systemic syndrome with peritoneal inflammation.\textsuperscript{113–115} Decreased reabsorption of proteins and liver disease with exudative enteropathy may also occur in the most severe cases.\textsuperscript{67,116–120} In addition to nonspecific signs of chronic heart failure, including digital clubbing, growth retardation, testicular atrophy, failure to develop male secondary sexual characteristics,\textsuperscript{121,122} and cachexia, more specific features of EMF include hypertrophy of the parotid gland, periorbital edema, and proptosis.

Atrial fibrillation occurs in >30% of cases.\textsuperscript{123} Conduction abnormalities such as first-degree atrioventricular block or right bundle-branch block are common,\textsuperscript{124} but EMF patients only rarely require a pacemaker. In advanced EMF with severe pulmonary hypertension (usually resulting from recurrent pulmonary embolism),\textsuperscript{125} ECG patterns include right ventricular hypertrophy and rightward frontal plane QRS axis deviation. The patient may die of progressive heart failure or experience sudden death caused by pulmonary thromboembolism\textsuperscript{125,126} or ventricular arrhythmias.\textsuperscript{11}

Pronounced cardiomegaly, bialateral dilatation, pulmonary infundibular dilatation, and postcapillary pulmonary hypertension are all typical radiological markers of biventricular EMF\textsuperscript{127} (Figure 4). Pleural and pericardial effusions are very common regardless of the laterality of the affected chambers.

Because echocardiography is almost always adequate for the diagnosis of EMF, invasive hemodynamic study with pressure assessment is no longer routinely used. When performed, the classic “dip and plateau” pattern (or square root sign) in the
Pathology

At pathological examination, the ventricles look small with grossly dilated atria, and on histopathology, endocardial thickening is considered the hallmark for identifying patients with EMF, a feature of advanced disease. Endocardial thickening usually corresponds microscopically to an increased number and abnormal stimulation of cardiac fibroblasts in the subendocardium, leading to enhanced collagen synthesis (Figure 6). Mild to moderate inflammatory infiltrates composed mainly of lymphocytes are prevalent along the interface between the endocardium and the myocardium. Myocardial lesions such as inflammatory infiltrates, interstitial fibrosis, and scars are prominent in areas adjacent to subendocardial fibrosis and altered vessels, suggesting that they likely occur in response to ischemic injury caused by microvascular changes. Cardiac tissue eosinophilia is rare in advanced disease. There is a lack of vessels in the outer endocardium, in clear contrast to rheumatic heart disease.

Morphological Assessment/Diagnosis

Echocardiography has become the mainstay of diagnosis, which allows optimal delineation of the morphology and noninvasive hemodynamics. Before 2008, the criteria described for diagnosing EMF applied only to the disease in its advanced stages. Major and minor criteria and a severity scoring system have since been proposed in an effort to capture several aspects of the natural history and phenotypes (Table 2). According to this classification, EMF is diagnosed when there are 2 major criteria or 1 major criterion with 2 minor criteria. Because some features seem to occur before severe chamber/valve distortion, the criteria have also been proposed for use in early diagnosis but have yet to be validated through follow-up studies.

Echocardiographically, in chronic forms, a restrictive syndrome with shrunken ventricles, severely dilated atria (Figure 2D), and major valve dysfunction is seen as a result of the global fibrosis. In advanced right-sided EMF, the cardiac apex becomes severely retracted, and the trabecular chamber is almost virtually obliterated, leading to dilatation of the outflow tract. Obliterative fibrosis of the posterior tricuspid pocket results in severe tricuspid regurgitation. The echocardiographic features for diagnosing right EMF also include right atrial enlargement (Figure 2E), restrictive inflow pattern, dilated inferior vena cava, and pericardial effusion. In very advanced cases, fibrosis may extend to the myocardium and atria. In biventricular EMF, progressive entrapment of the posterior mitral leaflet results in severe regurgitation (with a high-pitched regurgitation murmur) without ventricular remodeling as the left ventricle becomes small and stiff. The left atrium is markedly dilated, the mitral inflow pattern is restrictive, and pulmonary hypertension is common. In endemic countries, different forms of EMF may be misdiagnosed as dilated cardiomyopathy, constrictive pericarditis, or other restrictive cardiomyopathies such as amyloidosis, hemochromatosis, and sarcoidosis. An extremely enlarged right atrial chamber in EMF may also mimic Ebstein anomaly. Mild left EMF may also be difficult to distinguish from rheumatic heart disease affecting the mitral valve.

Although not available in most countries where EMF is common, cardiac magnetic resonance imaging provides additional value for the diagnosis of EMF, including the potential assessment of early disease. Cardiac magnetic resonance imaging outlines the degree of chamber distortion and the extent of thrombosis (Figure 5). Perfusion studies accurately map the hypoperfused myocardial areas and avascular structures, whereas late-gadolinium-enhancement images correlate with fibrosis. Cardiac magnetic resonance imaging would be an ideal tool for monitoring the response to treatment and for defining anatomic details before surgery. Computed tomography scans are more readily available but rarely used and may show the endocardial calcifications or the
intracavitary thrombi. On occasion, F-18 fluorodeoxyglucose positron emission tomography scan may be useful to rule out sarcoidosis as a differential diagnosis.

**Current Management Strategies**

Medical management consists of symptomatic treatment of heart failure (eg, diuretics, angiotensin-converting enzyme inhibitors) offered in combination with aspirin or anticoagulation in view of the potential for intracardiac thrombi. Paracentesis offers short-term relief only, because ascites often reaccumulates rapidly. By analogy with Loeffler syndrome, corticosteroids and immunosuppressive drugs may be helpful in the early stages, but there are no randomized, clinical trials to support their routine use.

Open heart surgery increases survival compared with medical treatment. Access to heart surgery, however, is severely limited in many endemic areas. Where expertise exists, EMF may be successfully treated with surgical endocardectomy and valve repair/replacement.

The use of cavopulmonary connections may be helpful in pure right-sided EMF with a small right ventricular cavity. Mitral and tricuspid valve replacement, frequently performed in the 1980s, is used less frequently now because of poor long-term outcomes from mechanical prostheses, especially in the tricuspid position. Although the early postoperative mortality may be up to 20% and variable rates of recurrence after surgery have been reported, timely surgical treatment still appears to be the only option to substantially improve outcomes at present. Patients with end-stage EMF may not be suitable for surgery, including those with clinical signs of advanced disease such as gross and long-standing ascites, chronic pulmonary thromboembolism, extensive endocardial fibrosis, right ventricular hypoplasia, or extreme cachexia. In the resource-poor

---

**Figure 4.** Chest-x ray features of advanced endomyocardial fibrosis (EMF). Left, A 10-year-old girl with severe cardiomegaly secondary to a giant left atrium and massive mitral insufficiency in left EMF. She was operated on with excision of the fibrotic endocardium, mitral valve repair/replacement, and atrial reduction. Right, A 12-year-old boy with severe cardiomegaly caused by aneurysmal right atrium in right EMF.

**Figure 5.** Cardiac magnetic resonance image (MRI) of endomyocardial fibrosis. Cardiac MRI cine images (A) and transesophageal echocardiography (B) showing a large apical thrombus attached to the fibrotic endocardium and reducing the left ventricular cavity.
settings where this disease predominates, instances of heart transplantation are at best anecdotal.\textsuperscript{159,160}

**Challenges and Perspectives**

EMF still causes significant morbidity among impoverished people in specific geographical pockets. Nevertheless, specific data on the burden of EMF are scant, and robust epidemiological population-based studies are urgently needed. Considering the high prevalence observed in some rural communities (up to 20%),\textsuperscript{3} we might expect that, even considering the highly heterogeneous distribution of the disease, EMF is likely to afflict hundreds of thousands of people in sub-Saharan rural Africa. This first view appears in contrast with a recent overview by Damasceno and colleagues\textsuperscript{24}: in The Sub-Saharan African Survey (THESUS-HF) study, which included >1000 patients with acute heart failure from 9 African countries, including Mozambique, Nigeria, Cameroon, and Uganda, only 1.3\% of all patients presented with EMF. It is noteworthy that this and other similar studies commenting on EMF prevalence in sub-Saharan Africa have focused on clinically overt heart failure. But, in order to assess true prevalence and to aim for meaningful prevention and early management strategies, it is important to account for subclinical disease. Furthermore, these studies have been carried out at hospital settings or in urban areas (such as in the THESUS-HF survey)\textsuperscript{24} and thus may not be truly reflective of overall prevalence in the general population. As a disease of the poorest population often found in remote rural areas, EMF may not be adequately captured by the aforementioned clinical studies. These potential sources of selection bias may explain the apparent discrepancy in prevalence figures. Providing accurate disease estimates will increase awareness among both health workers and policy makers and encourage them to tackle the disease. Further validation of the echocardiographic criteria defined recently\textsuperscript{3} will help strengthen epidemiological surveillance by providing a standardized tool for early diagnosis. Prospective cohorts with subclinical EMF detected by echocardiography would clarify the prognosis and either support or refute the need for systematic screening.

Secondly, there is a crucial need to further our understanding of the pathogenesis. Malnutrition and high cassava intake seem to act as independent cofactors in the pathogenesis of the disease regardless of other triggers such as infections and genetics, but this remains to be convincingly demonstrated. There is an urgent requirement for well-conducted case-control studies to identify predisposing factors. If EMF is an acquired condition, identification of a single factor or a combination of environmental/toxin-related factors could lead to effective eradication of the disease. Multicenter investigations into environmental and nutritional factors should be promoted to identify common backgrounds across different high-prevalence areas. Robust international collaborations are needed to achieve statistical power and to overcome inaccuracies caused by hidden bias.

Input from basic science researchers and geneticists, in combination with that from epidemiologists and clinicians, will help carry out well-directed studies in hospitals and in the community to address the issue of genetic susceptibility.\textsuperscript{281} Insights from molecular research addressing potential molecular mimicry and autoimmunity pathways and characterization of autoantibodies and their targets should shed light on the mechanisms involved. Investigations involving genomics and proteomics are likely to clarify the final common pathways leading to endocardial damage. For instance, markers such as C-reactive protein or inflammatory cytokines such as tumor necrosis factor-\(\alpha\) might play a central role in
episodic inflammatory flare-ups\textsuperscript{161} and be targeted for therapy. Inhibition of the protein FIP1L1-PDGFR\textalpha{}, a constitutively activated tyrosine kinase found in idiopathic hypereosinophilic syndromes, by imatinib is a potential example of such a therapeutic target,\textsuperscript{162} especially for patients with early EMF and prominent eosinophilia. These therapies, however, need to be proven and cost-effective to be viable in low-resource settings.

Until a specific treatment to halt the fibrotic process or a specific environmental factor triggering the pathogenesis is identified, cardiac surgery appears to be the only treatment option for advanced cases. The long-term efficiency of such a strategy, however, is unknown. Large numbers of surgical candidates may not be deemed fit for surgery when presenting late; therefore, early identification is key. In addition, access to cardiac surgery is extremely limited in low-income nations.\textsuperscript{46,163,164} Ultimately, improvement in living standards and access to care must be emphasized to prevent morbidity and mortality related to EMF, a still largely neglected disease.

**Conclusions**

Tropical EMF is a neglected disease of poverty that affects rural populations in tropical low-income countries, with some certain high-prevalence areas. EMF remains one of the most mysterious and poorly understood cardiovascular diseases, and increased awareness among health workers and policy makers is the need of the hour for the unhindered development of efficient preventive and therapeutic strategies. A better understanding of the disease, standardized training, and high-volume surgical expertise are needed in the attempt to improve outcomes from this devastating disease.

**Acknowledgments**

We thank the medical staffs of Mulago Heart Institute, Makerere University College Medical School, St. Raphael of St. Francis Nsambya Hospital in Kampala, Uganda, and Maputo Heart Institute, Maputo, Mozambique. We thank the Staff of AISPO at St. Francis Nsambya Hospital in Kampala, Uganda, and at San Raffaele Scientific Institute, Milan, Italy. We thank Professor Siew Yen Ho, head of Cardiac Morphology at Royal Brompton Hospital, London, UK, for the pathology picture. Finally, we would like to thank Cristina Amodeo, graphic designer of Figure 1.

**Disclosures**

None.

**References**


### Table 2. Criteria for Diagnosis and Assessment of the Severity of EMF\textsuperscript{*}

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Major criteria</strong></td>
<td></td>
</tr>
<tr>
<td>Endomyocardial plaques &gt;2 mm in thickness</td>
<td>2</td>
</tr>
<tr>
<td>Thin ((\leq 1) mm) endomyocardial patches affecting &gt;1 ventricular wall</td>
<td>3</td>
</tr>
<tr>
<td>Obliteration of the right ventricular or left ventricular apex</td>
<td>4</td>
</tr>
<tr>
<td>Thrombi or spontaneous contrast without severe ventricular dysfunction</td>
<td>4</td>
</tr>
<tr>
<td>Retraction of the right ventricular apex (right ventricular apical notch)</td>
<td>4</td>
</tr>
<tr>
<td>Atrioventricular valve dysfunction caused by adhesion of the valvular apparatus</td>
<td>1–4†</td>
</tr>
<tr>
<td><strong>Minor criteria</strong></td>
<td></td>
</tr>
<tr>
<td>Thin endomyocardial patches localized to 1 ventricular wall</td>
<td>1</td>
</tr>
<tr>
<td>Restrictive flow pattern across mitral or tricuspid valves</td>
<td>2</td>
</tr>
<tr>
<td>Pulmonary valve diastolic opening</td>
<td>2</td>
</tr>
<tr>
<td>Diffuse thickening of the anterior mitral leaflet</td>
<td>1</td>
</tr>
<tr>
<td>Enlarged atrium with normal-sized ventricle</td>
<td>1</td>
</tr>
<tr>
<td>M-movement of the interventricular septum and flat posterior wall‡</td>
<td>2</td>
</tr>
<tr>
<td>Enhanced density of the moderator or other intraventricular bands</td>
<td>1</td>
</tr>
</tbody>
</table>


\*A definite diagnosis of endomyocardial fibrosis was made in the presence of 2 major criteria or 1 major criterion associated with 2 minor criteria. A total score of <8 indicates mild endomyocardial fibrosis; a score of 8 to 15, moderate disease; and a score >15, severe disease.

†The score is assigned according to the severity of atrioventricular regurgitation.

‡M-movement of the interventricular septum refers to a pattern of movement observed on M-mode echocardiography that is thought to be attributable to obliteration or restriction of the left ventricular apex combined with mitral regurgitation.


Freers J, Mayanja-Kizza H, Gerwing E. Endomyocardial fibrosis: is there when striking ascites with little or no peripheral oedema? Lancet. 1996;347:197.


114. Marijon E, Hauze AO, Ferreira B. Typical clinical aspect of endomyo-
120. Salemi VM, Rochitte CE, Barbosa MM, Mady C. Images in cardiol-
121. Bolarin DM, Andy JJ. Clinical feminization and serum testosterone lev-
126. Marijon E, Jani D, Ou P. Endomyocardial fibrosis: progression to restric-
127. Rost C, Bachmann S, Flachskampf FA. Obstructive endocardial throm-
128. Silvas K, Damasceno A, Mayosi BM. Epidemiology and etiology of car-
129. Buturak A, Saygili O, Ulus S, Kalfa M, Karabulut H, Alcan C, Dagdelen S, Aksu K. Right ventricular endomyocardial fibrosis mim-
130. Estornell J, López MP, Dícanta F, Igal B, Martínez V, Sonilleva A. Usefulness of magnetic resonance imaging in the assessment of endomyo-
132. Salemi VM, Rochitte CE, Shiozaki AA, Andrade JM, Parga JR, de Ávila LF, Benvenuti LA, Cestari IN, Piccard MI, Kim RJ, Mady C. Late gado-
133. Genée O, Fichert J, Alison D. Images in cardiovascular medicine: cardiac magnetic resonance imaging and eosinophilic endomyo-
134. León D, Martin M, Corrales C, Samanta M, Testolla S, Lambert JL. Usefulness of cardiac MRI in the early diagnosis of endomyocar-
135. D’Silva SA, Kohli A, Dalvi BV, Kale PA. MRI in right ventricular endo-
139. Metras D, Coulibaly AO, Ouattara K. The surgical treatment of endo-
140. Valiathasan MS, Balakrishnan KG, Sarkankumar R, Kartha CC. Surgical treat-
141. Cheriyan SM, Jagannath BR, Nayar S, Cheriyan KM. Successful reop-
143. Joshi R, Abraham S, Kumar AS. New approach for complete endocardi-
144. Graham JM, Lawanag MS, Fettie NM, Debacke GM. Management of endomyocardial fibrosis: successful surgical treatment of biventricular involvement and consideration of the superiority of operative interven-
146. Dises EA, Buffolo E, Moraes Neto F, Rodrigues JV, Gomes CA, Branco JN, Aguilar L. Recurrence of fibrosis after endomyocardial fibro-
147. Tang A, Karski J, Butany J, David T. Severe mitral regurgita-
Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives
Antonio Grimaldi, Ana Olga Mocumbi, Juergen Freers, Matthias Lachaud, Mariana Mirabel, Beatriz Ferreira, Kumar Narayanan, David S. Celermajer, Daniel Sidi, Xavier Jouven and Eloi Marijon

Circulation. 2016;133:2503-2515
doi: 10.1161/CIRCULATIONAHA.115.021178
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/133/24/2503

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/